A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19
Authors:
Open Access
- 19 December 2022
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 128, 148-156
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivoNature, 2022
- Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsNew England Journal of Medicine, 2021
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsNew England Journal of Medicine, 2021
- Mechanisms of SARS-CoV-2 entry into cellsNature Reviews Molecular Cell Biology, 2021
- High-dimensional characterization of post-acute sequelae of COVID-19Nature, 2021
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19JAMA, 2021
- Persistent Symptoms in Patients After Acute COVID-19JAMA, 2020
- New potential therapeutic applications of WX-UK1 as a specific and potent inhibitor of human trypsin-2 and human trypsin-3Molecular Cancer Therapeutics, 2018
- The Oral Serine Protease Inhibitor WX-671 – First Experience in Patients with Advanced Head and Neck CarcinomaBreast Care, 2008
- Synthesis and Structure−Activity Relationships of Potent Thrombin Inhibitors: Piperazides of 3-AmidinophenylalanineJournal of Medicinal Chemistry, 1997